Safety and efficacy of SGLT2 Inhibitors (empagliflozin, dapagliflozin and canagliflozin) in diabetic patients
Latest Information Update: 23 Jul 2020
At a glance
- Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 23 Jul 2020 New trial record
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association